The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus

American Journal of Hypertension

Volumn 12, Issue 4 I, 1999, Pages 348-355

  Price, Deborah A ^a   De'Oliveira, Jose M F ^a   Fisher, Naomi D L ^a   Williams, Gordon H ^a   Hollenberg, Norman K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiotensin II; Plasma renin activity; Type II diabetes

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE; RENIN;

ADULT; ARTICLE; CLINICAL ARTICLE; ENZYME INHIBITION; FEMALE; HUMAN; HYPERTENSION; KIDNEY CIRCULATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASODILATATION; ZONA GLOMERULOSA;

NON-PROGRAMMATIC;

ADULT; AGED; ALDOSTERONE; ANGIOTENSIN II; DIABETES MELLITUS, TYPE 2; DIET, SODIUM-RESTRICTED; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POSTURE; RENIN; RENIN-ANGIOTENSIN SYSTEM; VASOCONSTRICTOR AGENTS; ZONA GLOMERULOSA;

EID: 0032953024     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00265-9     Document Type: Article

References (39)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
2. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996;156:286-289.
3. Mogensen CE: Renoprotective role of ACE inhibitors in diabetic nephropathy. Br Heart J 1994;72(suppl):38-45.
4. Neilsen FS, Rossing P, Gall MA, Skott P, Parving HH: Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997;46:1182-1188.
5. Yokoyama H, Tomonaga O, Hirayama M, et al: Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 1997;40:405-411.
6. Marre M, Bernadet P, Gallois Y, et al: Relationship between Ang I converting enzyme gene polymorphism in the plasma levels, and diabetic complications. Diabetes 1994;43:384-388.
7. Krolewski A, Canessa M, Warram JH, et al: Predisposition of hypertension and susceptibility to renal disease in IDDM. N Engl J Med 1988;318:140-145.
8. Viberti GC, Earle K: Predisposition to essential hypertension and the development of DKD. J Am Soc Nephrol 1992;3(suppl):27-33.
9. Jeffers BW, Estacio RO, Reynolds MV, Schrier RW: Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy. Kidney Int 1997;52:473-477.
10. De'Oliveira JM, Price DA, Fisher NDL, et al: Autonomy of the renin system in type II diabetes: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int 1997;52:771-777.
11. Price DA, Porter L, De'Oliveira J, et al: The paradox of the low-renin state: hormonal and renal responses to an AngII antagonist, irbesartan, in diabetic nephropathy. J Am Soc Nephrol 1996;7:163.
12. Hollenberg NK, Williams GH: Abnormal renal function. Na-volume homeostasis, and renin system behavior in normal-renin essential hypertension, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management. New York, Raven, 1990, pp 1349-1370.
13. Hollenberg NK: Genes, hypertension,and intermediate phenotypes. Curr Opin Cardiol 1996;11:457-463.
14. Hollenberg, NK, Moore TJ, Shoback D, et al: Abnormal renal Na handling in essential hypertension. Relation to failure of renal and adrenal modulation of responses to AngII. Am J Med 1986;81:412-418.
15. Dluhy RG, Hopkins PN, Hollenberg NK, et al: Heritable abnormalities of the RAAS in essential hypertension. J Cardiovasc Pharmacol 1988;12(suppl):149-154.
16. Hopkins PN, Lifton RP, Hollenberg NK, et al: Blunted renal vascular response to AngII is associated with a common variant of the AGT gene and obesity. J Hypertens 1996;14:199-207.
17. Correa-Rotter R, Hostetter TH, Rosenberg ME: Renin and AGT gene expression in experimental IDDM. Kidney Int 1992;41:796-804.
18. Ballerman B, Skorecki KL, Brenner BM: Reduced glomerular AngII receptor density in early untreated IDDM in the rat. Am J Physiol 1984;247:F110-F116.
19. Wilkes B: Reduced glomerular AngII receptor density in IDDM in the rat: time course and mechanism. Endocrinol 1987;120:1291-1298.
20. Williams GH, Dluhy RG, Lifton RP, et al: Non-modulation as an intermediate phenotype in essential hypertension. Hypertension 1992;20:788-796.
21. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-1057.
22. Shoback DM, Williams GH, Moore TJ, et al: Defect in the sodium-modulated tissue responsiveness to AngII in essential hypertension. J Clin Invest 1983;72:2115-2124.
23. Emanuel R, Cain JP, Williams GH: Double antibody radioimmunoassay of renin activity and AngII in human peripheral plasma. J Lab Clin Med 1973;81:632-640.
24. Underwood RH, Williams GH: The simultaneous measurement of aldosterone, cortisol, and corticosterone in human peripheral plasma by displacement analysis. J Lab Clin Med 1972;70:848-862.
25. Perez GO, Lespier L, Jacobi J: Hyporeninemia and hypoaldosteronism in diabetes mellitus. Arch Intern Med 1977;137:852-855.
26. Christlieb AR: Nephropathy, the renin system, and hypertensive vascular disease in diabetes mellitus. Cardiovasc Med 1978;2:417-431.
27. Bjorck S: The renin-angiotensin system in diabetes mellitus: a physiological and therapeutic study. Scand J Urol Nephrol 1990;126(suppl):1-50.
28. Sealey JE, Blumenfeld JD, Bell GM, et al: On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconcentration-volume relationship. J Hypertens 1998;6:763-777.
29. Lush DJ, King JA, Fray JCS: Pathophysiology of low renin syndromes: sites of renal renin secretory impairment and prorenin overexpression. Kidney Int 1993;43:983-999.
30. Weidmann P, Ferrari P, Shaw SG: Renin in diabetes mellitus, in Robertson JIS, Nicholls MG (eds): The Renin-Angiotensin System. New York, Raven, 1993, pp 75.1-75.26.
31. Trujillo A, Eggena P, Barrett J, Tuck M: Renin regulation in type II diabetes mellitus: influence of dietary sodium. Hypertension 1989;13:200-205.
32. Fernandez-Cruz A, Noth RH, Lassman MN, et al: Low plasma renin activity in normotensive patients with diabetes mellitus: relationship to neuropathy. Hypertension 1981;3:87.
33. Nakamura T, Ichikawa S, Sakamaki T, et al: Effects of insulin on plasma renin activity, plasma atrial natriuretic peptide and body fluid volume in diabetes mellitus. Jpn Heart J 1990;31:671-682.
34. Miller JA, Floras JS, Zinman B, et al: Effect of hyperglycemia on arterial pressure, plasma renin activity and renal function in early diabetes. Clin Sci 1996;90:189-195.
35. DeFronzo RA, Cooke CR, Andres R, et al: The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975;55:845-855.
36. Smoller S, Rashid K, Perez GO, et al: Blunted kaliuresis after an acute oral potassium load in diabetes mellitus. Am J Med Sci 1988;295:114-121.
37. Hasslacher C, Ritz E, Tschope W, et al: Hypertension in diabetes mellitus. Kidney Int 1988;25(suppl):S133-S137.
38. Lebovitz HE, Viegmann TB, Cnaan A: Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int 1994;45(suppl):150-155.
39. Estacio RO, Jeffers BW, Hiatt WR, et al: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-652.